Diabetes Medications and GLP-1 Side Effects: Why Your Whole Medication List Matters

If you take a GLP-1 medication for type 2 diabetes, there is a good chance it isn't your only diabetes medication. Metformin, SGLT2 inhibitors, sulfonylureas, alpha-glucosidase inhibitors, insulin, and other medications may be used alongside GLP-1 therapy depending on your individual needs. That matters when gastrointestinal symptoms develop. Some diabetes medications can cause gastrointestinal symptoms of their own, making it difficult to determine whether nausea, diarrhea, bloating, or abdominal discomfort is coming from the GLP-1, another medication, or a combination of factors.

WEIGHT MANAGEMENT

Sarina Helton, MSN, APRN, FNP-C, CAE-OM

10/7/20264 min read

What Does the Research Show?

A 2025 study specifically examined risk factors for gastrointestinal adverse events among 215 adults with type 2 diabetes receiving semaglutide.

Forty-one participants, or approximately 19%, experienced gastrointestinal adverse events attributed to semaglutide.

Reported symptoms included:

Abdominal pain
Abdominal bloating or distention
Diarrhea
Nausea and vomiting
Decreased appetite

Researchers then looked for characteristics associated with a greater likelihood of developing these symptoms.

After adjusting for other factors, three independent risk factors emerged:

Preexisting gastrointestinal disease
Alcohol consumption
Concurrent use of alpha-glucosidase inhibitors

People taking an alpha-glucosidase inhibitor alongside semaglutide had approximately three times the odds of developing gastrointestinal adverse events in this study population.

That does not mean the combination will cause GI problems in every patient. This was a relatively small study involving people with type 2 diabetes, and the findings should not automatically be generalized to every patient or every GLP-1 medication.

What Are Alpha-Glucosidase Inhibitors?

Alpha-glucosidase inhibitors are diabetes medications that slow the digestion and absorption of carbohydrates in the small intestine.

Examples include:

Acarbose
Miglitol

Because of how these medications work, gastrointestinal symptoms are already well-recognized adverse effects.

These can include:

Gas
Bloating
Abdominal discomfort
Diarrhea

Adding a medication that can also affect gastrointestinal function may contribute to a greater overall GI symptom burden in some patients.

That does not mean these medications should never be used together.

It means their combined effects deserve consideration when symptoms develop.

What About Metformin?

Metformin deserves special attention because it is one of the most commonly prescribed medications for type 2 diabetes and is frequently used alongside GLP-1 medications.

Metformin can cause:

Diarrhea
Nausea
Abdominal discomfort
Bloating
Reduced appetite

So if someone taking metformin develops diarrhea or nausea after beginning a GLP-1 medication, it may be tempting to assume that the combination itself places them at particularly high risk.

The evidence isn't that simple.

In the 2025 semaglutide study, concurrent metformin use was not significantly different between patients who did and did not develop GI adverse events. The same was true for several other diabetes medication classes examined in the study.

Therefore, I would not label metformin itself as a proven risk factor for GLP-1 intolerance.

The more useful clinical point is that metformin can independently produce some of the same symptoms, which can complicate the picture when a patient begins GLP-1 therapy.

Symptom Timing Can Provide Important Clues

Imagine that you've taken metformin for several years without problems.

You start semaglutide and develop nausea three days later.

That timing makes the new medication an obvious consideration.

But now imagine your metformin dose was increased at the same time.

Or you recently started acarbose.

Or your GLP-1 dose was increased after several symptom-free months.

Suddenly, identifying the cause becomes more complicated.

Your healthcare provider may ask:

When did the symptoms begin?
Which medications were started recently?
Were any doses recently increased?
Did symptoms begin after a GLP-1 dose increase?
Were you already experiencing GI symptoms before treatment?
Have your eating patterns changed?
Are symptoms associated with taking a particular medication or eating certain foods?

The timeline often matters as much as the medication list itself.

Don't Forget About Hypoglycemia Risk

Gastrointestinal symptoms aren't the only reason your complete diabetes medication regimen matters.

GLP-1 medications used alone generally have a relatively low risk of causing hypoglycemia.

However, the risk increases when GLP-1 medications are combined with medications that can independently lower blood glucose, particularly insulin or sulfonylureas.

When a new glucose-lowering medication is started, the American Diabetes Association recommends reassessing medications with a higher risk of hypoglycemia, including insulin, sulfonylureas, and meglitinides, and adjusting treatment when appropriate.

This is a different issue from GI intolerance, but it is another important reason your healthcare provider needs to know exactly which diabetes medications you're taking.

Your GLP-1 cannot be evaluated in isolation from the rest of your diabetes treatment.

Don't Automatically Stop Your Diabetes Medication

If gastrointestinal symptoms develop after starting or increasing a GLP-1 medication, don't automatically stop metformin or another diabetes medication.

Likewise, don't automatically assume the GLP-1 needs to be discontinued.

Your healthcare provider may need to look at:

Which symptom you're experiencing
When it started
How severe it is
Your GLP-1 dose and titration schedule
Your other diabetes medications
Recent medication changes
Your glucose levels
Your hydration and nutritional intake
Preexisting gastrointestinal conditions
Other gastrointestinal conditions

The appropriate solution depends on what is actually causing the problem.

Your Whole Medication List Matters

GLP-1 medications don't exist in isolation.

A person taking semaglutide or tirzepatide may also be taking several medications for diabetes and other health conditions.

Some may affect the gastrointestinal tract. Others may produce symptoms that look remarkably similar to GLP-1 side effects.

When new GI symptoms appear, the question to ask yourself may be "What has changed across my entire medication and treatment plan?"

That is one reason medication reconciliation matters before starting treatment and whenever new side effects develop.

The Takeaway

Some diabetes medications can contribute to gastrointestinal symptoms independently of GLP-1 therapy.

A 2025 semaglutide study found that concurrent use of alpha-glucosidase inhibitors was independently associated with increased odds of gastrointestinal adverse events, while concurrent metformin use was not identified as a significant predictor in that study.

This doesn't mean patients taking alpha-glucosidase inhibitors cannot use semaglutide, and it doesn't mean metformin can never contribute to GI symptoms.

It means the clinical picture is more complicated than blaming one medication.

Your whole medication list matters, not just your GLP-1.

Medical Disclaimer

This information is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.

Do not stop, start, or change diabetes medications based on this information without discussing the change with your healthcare professional. Changes to diabetes medications can affect blood glucose and may result in hyperglycemia or hypoglycemia.

Seek medical attention for severe, persistent, or rapidly worsening symptoms.

References

Yue D, Hua X, Zhu L, et al. Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;16:1684395.
Full-text article in Frontiers

American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1).

American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1).
Full-text ADA Standards chapter

Ready to Start Your Weight Management Journey?

GLP-1 medications can be powerful tools, but the right medication, dose, and rate of dose escalation can be different for each person.

At Optima Vida Healthcare, weight management is individualized based on your health history, previous treatments, response to medication, side effects, goals, and long-term needs.

Treatment may include GLP-1 or other weight-management medications when medically appropriate, along with ongoing monitoring and support.

Start Your Weight Management Evaluation →

Or Visit www.ovhmed.com for more information.

Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare provider.